Dr. Csimma is an experienced biopharmaceutical leader and Board Director. She currently serves on the Board of Directors of Idera Pharmaceuticals, as Board Chair of Caraway Therapeutics and Forendo Pharma, and on advisory boards, including: the Muscular Dystrophy Association Venture Philanthropy Scientific Advisory Committee; the Executive Oversight Board to the National Institutes of Health (NIH); NeuroNext Network; the Harvard and Brigham and Women’s Hospital MRCT Center External Advisory Board; and the TREAT-NMD Advisory Committee for Therapeutics (TACT). She was previously the Executive Chair of the Board of Directors of Exonics Therapeutics, a Director of Juniper Pharmaceuticals (acquired by Catalent), Vtesse (acquired by Sucampo Pharmaceuticals) and Cydan, where she was also President and founding CEO. She was also the Vice President of Drug Development at Virdante Pharmaceuticals Inc (acquired by Momenta), Principal at Clarus Ventures LLC, and held roles in Clinical Development and Translational Research at Wyeth (now Pfizer), Genetics Institute and Dana-Farber Cancer Institute. Dr. Csimma holds both a Doctor of Pharmacy and a Bachelor of Science in Pharmacy from the Massachusetts College of Pharmacy and Allied Health Sciences, as well as a Master of Health Professions from Northeastern University.